DOCSLIB.ORG

Preliminary Agenda Best of Switzerland Conference

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preliminary Agenda Best of Switzerland Conference Preliminary Agenda Best of Switzerland Conference Thursday, 5 September 2019 07.45 Registration and Welcome Coffee I Foyer and Airbus Airbus 08.15 UBS Group AG Axel P. Lehmann, President Personal & Corporate Banking and President UBS Switzerland Zeppelin I Zeppelin II 09.00 Partners Group Alcon (Fireside chat) Philip Sauer, Co-Head Group Finance & Tim Stonesifer, Chief Financial Officer Corporate Development Michael Onuscheck, President, Global Business & Alex Soppera, Corporate Development Innovation Christina Cheng, Global Head, Investor Relations 09.45 VAT Group AG (Fireside chat) Geberit AG Mike Allison, Chief Executive Officer Roland Iff, Chief Financial Officer 10.30 Coffee Break I Airbus 11.00 Dufry AG Sulzer Yves Gerster, Chief Financial Officer Greg Poux-Guillaume, Chief Executive Officer Renzo Radice, Head of IR and Corporate Communications 11.45 INFICON Holding AG Roche Lukas Winkler, Chief Executive Officer Karl Mahler, Head of Investor Relations 12.30 Buffet Lunch I Airbus, Restaurant and outside area 13.30 Cembra Money Bank (Fireside chat) Vifor Pharma Robert Oudmayer, Chief Executive Officer Colin Bond, Chief Financial Officer Pascal Perritaz, Chief Financial Officer 14.15 Leonteq AG Novartis Lukas Ruflin, Chief Executive Officer Thomas Hungerbühler, Investor Relations Dominik Ruggli, Head Investor Relations and Communications 15.00 Coffee Break I Restaurant and outside area 15.30 Vontobel Holding AG (Fireside chat) Givaudan (Fireside chat) Martin Sieg, Chief Financial Officer Peter Wullschleger, Head of Investor Relations 16.15 Comet (Fireside chat) Heinz Kundert, Chief Executive Officer ad interim Beat Malacarne, Chief Financial Officer 17.00 Apéro Riche and Networking I Restaurant and outside area Page 1 of 4 Companies available for meetings only (Thursday) Autoneum Holding AG Dr. Martin Zwyssig, Chief Financial Officer Baloise Holding AG Carsten Stolz, Group Chief Financial Officer Markus Holtz, Head of Investor Relations Basilea Pharmaceutica International Ltd David Veitch, Chief Executive Officer Adesh Kaul,Chief Financial Officer BB Biotech AG Dr. Daniel Koller, Chief Executive Officer Dr. Christian Koch, Portfolio Manager Dr. Silvia Siegfried, Investor Relations Idorsia Pharmaceuticals Ltd Andrew Weiss, Head of Investor Relations and Corporate Communications Molecular Partners Patrick Amstutz, Chief Executive Officer Andreas Emmenegger, Chief Financial Officer Phoenix Mecano Dr. Rochus Kobler, Chief Executive Officer Schindler Holding AG Marco Knuchel, Head Investor Relations Swiss Life Holding AG Heidi Hinterhuber, Head of Investor Relations Olga Schmidtberger, Manager Investor Relations Swiss Prime Site Markus Waeber, Head Investor Relations & Communications Mladen Tomic, Head Corporate Communications Zurich Insurance Group Richard Burden, Head of Investor Relations and Rating Agency Management Gianni Vitale, Senior Investor Relations Officer Page 2 of 4 Friday, 6 September 2019 08.30 Registration and Welcome Coffee I Airbus Zeppelin I Zeppelin II 09.00 Georg Fischer AG Galenica AG (Fireside chat) Andreas Müller, Chief Executive Officer Felix Burkhard, Chief Financial Officer Mads Joergensen, Chief Financial Officer 09.45 SFS Group AG Landis+Gyr AG Rolf Frei, Chief Financial Officer Richard Mora, Chief Executive Officer Benjamin Sieber, Head of Investor Relations 10.30 Coffee Break I Airbus 11.00 Arbonia AG U-Blox (Fireside chat) Alexander von Witzleben, Chief Executive Officer Thomas Seiler, Chief Executive Officer Daniel Wüest Chief Financial Officer Fabienne Zürcher, Head of Corporate Communications 11.45 Stadler Rail Zur Rose (Fireside chat) Thomas Ahlburg, Group Chief Executive Officer Walter Oberhänsli, Chief Executive Officer Raphael Widmer, Group Chief Financial Officer Marcel Ziwica, Chief Financial Officer 12.30 Buffet Lunch I Airbus, Restaurant and outside area 13.30 Oerlikon (Fireside chat) Straumann Holding AG Andreas Schwarzwälder, Head of Investor Relations Peter Hackel, Chief Financial Officer Fabian Hildbrand, Head of Investor Communication 14.15 SIG Combibloc Group AG Adecco Group Rolf Stangl, Chief Executive Officer Hans Ploos van Amstel, Chief Financial Officer Samuel Sigrist, Chief Financial Officer Nicholas de la Grense, Head of Investor Relations 15.00 Presentations end – Meetings still in progress Page 3 of 4 Companies available for meetings only (Friday) Ascom Holding AG Dr. Daniel Lack, Senior VP Legal & Communications/IR Francis Schmeer, Chief Sales & Marketing Officer Bachem Holding AG Stephan Schindler, Chief Financial Officer Anne-Kathrin Stoller, Chief Marketing Officer Burckhardt Compression Marcel Pawlicek, Chief Executive Officer Rolf Brändli, Chief Financial Officer EFG International AG Dimitris Politis, Chief Financial Officer Jens Brueckner, Head of Investor Relations Flughafen Zürich AG Stefan Weber, Head IR, Treasury & Risk Management Marcel Heinzer, Financial Analyst GAM Holding AG Richard McNamara, Chief Financial Officer Patrick Zuppiger, Head of Group Communications and Investor Relations Julius Baer Group Dieter Enkelmann, Chief Financial Officer Alexander C. van Leeuwen, Head of Investor Relations Polyphor Giacomo di Nepi, Chief Executive Officer PSP Swiss Property Giacomo Balzarini, Chief Executive Officer Sensirion Holding AG Marc von Waldkirch, Chief Executive Officer Andrea Wüest, Director Investor Relations Sonova Holding AG Thomas Bernhardsgrütter, Head of Investor Relations Sunrise Olaf Swantee, Chief Executive Officer Uwe Schiller, SVP Finance & Investor Relations Stephan Gick, Investor Relations Manager Swiss Re Martin Müller, CFO Corporate Solutions Daniel Bischof, Investor Relations Senior Manager Agenda is preliminary and subject to change. © UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. All pictures or images presented herein, are for illustrative purposes only. No relationship, association, sponsorship, or endorsement is suggested or implied between UBS and any landmarks or properties, or with their respective owners, organizations, management, sponsors, investors or patrons. Page 4 of 4 .
Load more

Recommended publications
  • Media Release
    CREDIT SUISSE AG Paradeplatz 8 Tel. +41 844 33 88 44 P.O. Box Fax +41 44 333 88 77 CH-8070 Zurich [email protected] Switzerland Rating Overview of Swiss Companies Company CS Rating CS Outlook Changes since June 2009 S&P Moody's ABB Low A Stable A–, Stable A3, Stable Adecco Mid BBB Negative Outlook changed from Stable to Negative BBB–, Stable Baa3, Stable AFG Low BBB Stable Outlook changed from Negative to Stable n.r. n.r. Alpiq High A Stable n.r. n.r. Aryzta High BBB Stable Coverage initiation n.r. n.r. Axpo Low AA Stable n.r. n.r. Bâloise Low A Stable A–, Stable1 n.r. BKW Low AA Stable n.r. n.r. –1 notch, outlook changed from Negative to Bobst Group Low BBB Stable n.r. n.r. Stable Bucher Industries High BBB Stable n.r. n.r. CKW n.r. n.r. Drop coverage Clariant High BB Stable BBB–, Stable Ba1, Stable Coop Low A Stable n.r. n.r. –1 notch, outlook changed from Stable to Edipresse High BB Negative n.r. n.r. Negative –1 notch, outlook changed from Negative to EGL Low A Stable n.r. n.r. Stable EMS Chemie Low A Stable Outlook changed from Negative to Stable n.r. n.r. Energiedienst Low A Stable n.r. n.r. EOS n.r. n.r. Drop coverage Flughafen Zurich Mid BBB Stable BBB+, Positive n.r. Forbo Mid BBB Stable n.r. n.r. Geberit High BBB Stable A–, Stable n.r.
    [Show full text]
  • Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi
    Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation South San Francisco, CA -- May 21, 2019 -- Verily, an Alphabet company, today announced strategic alliances with Novartis (NYSE: NVS), Otsuka (NYSE: OTSKY), Pfizer Inc. (NYSE: PFE) and Sanofi (EURONEXT: SAN, NASDAQ: SNY) to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of a clinic. Across the United States, the number of people participating in clinical research -- including clinical trials and observational studies -- is less than 10% of the population.1 In addition to low participation, challenges in research include data fragmentation, inefficient operations and limited value for patients. Alongside academic research institutions, patient-advocacy groups and health systems, Verily and its industry partners aim to implement a more patient-centric, technology-enabled approach to research, and increase the number and diversity of clinical research participants. They will also explore novel approaches to generating real-world evidence using the Baseline Platform to collect, organize and activate health information from electronic health records, sensors and other digital sources. Over the coming years, Novartis, Otsuka, Pfizer and Sanofi each plan to launch clinical studies leveraging the platform across diverse therapeutic areas, such as cardiovascular disease, oncology, mental health, dermatology and diabetes.
    [Show full text]
  • Private Capital in Switzerland
    DOWNLOAD THE DATA PACK PRIVATE CAPITAL IN SWITZERLAND KEY FACTS 52 €632mn €1.9bn Total number of Average size of Average allocation to Switzerland-based Switzerland-based funds private capital among funds in market, closed in 2018 YTD across Switzerland-based targeting an aggregate all private capital. investors. €13bn. Fig. 2: Annual Switzerland-Based Private Capital Fig. 1: Annual Switzerland-Based Private Capital Fundraising by Asset Class, 2008 - 2018 YTD Fundraising, 2008 - 2018 YTD (As at October 2018) (As at October 2018) 39 100% 5 1.2 40 22 5.9 35 34 Natural Resources 35 32 33 30 31 80% 14.6 30 26 36 Private Debt 25 24 24 10.4 19 60% 20 16 Infrastructure 15 14.4 9.3 8.4 9.6 9.5 40% 10 7.8 6.9 6.2 6.8 Real Estate 5.8 212 55.2 5 2.5 Proportion of Total 0 20% Private Equity & 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Venture Capital 0% YTD Year of Final Close No. of Funds Aggregate Capital No. of Funds Closed Aggregate Capital Raised (€bn) Closed Raised (€bn) Source: Preqin Pro Source: Preqin Pro Fig. 3: Switzerland-Based Private Capital: Median Net Fig. 4: Switzerland-Based Private Capital Assets under IRRs by Vintage Year (As at October 2018) Management by Asset Class, 2008 - 2018 18% 17.0%16.7% 50 16% 14.3% 40 14% 11.5% 11.3% 30 12% 10.9% 10.5% 10% 9.2% (€bn) 20 8.1% 8.5% 8% 6.4% 10 6% Assets under Management 4% 0 Median Net IRR since Inception 2% Dec-08 Dec-09 Dec-10 Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 0% Mar-18 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Private Equity Real Estate Infrastructure Vintage Year Private Debt Natural Resources Source: Preqin Pro Source: Preqin Pro 1 ©Preqin Ltd.
    [Show full text]
  • Update on Partners Group
    Update on Partners Group February 2021 Gonzalo Fernández Castro Private Equity Americas | Hal Avidano Co-Head Private Equity Integrated Investments Americas UPDATE ON PARTNERS GROUP 2 Table of contents 1 Overview 2 Clients 3 Industry 4 Investments 5 ESG 6 Financials OVERVIEW 3 About us Dedicated to private markets Leveraging strong resources • Our AuM stands at USD 109 billion:1 USD 52 billion in • We have over 1,500 employees worldwide2 across 20 corporate equity & USD 57 billion real assets / financing offices and over 750 private markets professionals • We leverage our database of over 36,000 private markets • Our platform, portfolio and network provide extensive assets to generate attractive deal flow synergies and opportunities for owners and entrepreneurs We have a global presence with 20 offices across key investment regions Tokyo Shanghai Seoul Toronto Dubai Denver London New York Mumbai Guernsey Luxembourg Manila Houston Munich Paris Singapore Zug Milan São Paulo Sydney Americas Europe Asia Pacific For illustrative purposes only. Source: Partners Group (2020). 1 Unaudited, inclusive of all Partners Group affiliates, as of 31 December 2020. 2 As of 31 December 2020. OVERVIEW 4 About our portfolio Partner to business Entrepreneurial ownership Corporate assets (USD 52 billion AuM1) Healthcare Industrials Consumer & services Technology Real assets / financing (USD 57 billion AuM2) Infrastructure Real estate Real asset services Financing We are "responsible for the dreams" of the 200,000+ partners and employees who work alongside us in our portfolio For illustrative purposes only. Source: Partners Group (2019). 1 Corporate equity includes Partners Group's private equity asset under management as of 31 December 2020.
    [Show full text]
  • DWS (CH) II Small and Mid Caps Switzerland
    Marketing Material DWS (CH) II Small and Mid Caps Switzerland Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Performance Investment Policy Performance - Share Class FD (in %) The goal of the sub-fund is primarily to achieve long-term growth in Swiss Francs through investment in a portfolio of stocks from Swiss issuers that are listed in a representative Swiss equities index of small and medium enterprises or the small and mid- cap subindex of a Swiss equities index (“the benchmark”). The investment strategy is based on a transparent and comprehensible investment process, focuses on stock selection. Fund Benchmark (since 09/08/2006): SPI EXTRA Total Return (RI) Past performance is no indication of current or future performance, and the performance data do not take account of the commissions and costs Fund Management's Comment incurred on the issue and redemption of units. For detailed comments on the fund and its corresponding markets please see the annual report. Cumulative performance (in %) - share class FD 1 m 1 y 3 y 5 y s. Inception YTD 3 y avg 5 y avg 2017 2018 2019 2020 CHF 3.0 42.7 36.1 77.7 421.8 29.6 10.8 12.2 29.9 -21.6 29.3 1.8 EUR 2.7 42.0 42.2 80.2 650.5 30.2 12.5 12.5 19.4 -18.6 33.7 2.2 BM IN CHF 2.5 34.9 39.1 90.5 284.2 23.7 11.6 13.8 29.7 -17.2 30.4 8.1 Further Characteristics (3 years) / VAR (1 year) - share class FD Volatility 18.36% Maximum Drawdown -21.26% VAR (99%/10 days) 7.23% Sharpe Ratio -- Information Ratio -0.16 Correlation Coefficient 0.97 Alpha -1.26% Beta 1.05 Tracking Error
    [Show full text]
  • Market Notice Date: 14 November 2019 Market Notice Number: 112/2019
    Market Notice Date: 14 November 2019 Market Notice Number: 112/2019 Equiduct Universe Change Please see today's changes below effective 18 November 2019: Trading Reporting MIC Settlement Trading Settlement Tick Size Change/ Security Name ISIN Home Market Symbol Country Currency Currency table Action ABB LTD ABBNz CH0012221716 XSWX EQTB CH CHF CHF ESMA_E Deletion ABB ABBs CH0012221716 XSTO EQTB SE SEK SEK ESMA_E Deletion ADECCO SA ADENz CH0012138605 XSWX EQTC CH CHF CHF ESMA_E Deletion AMS AG AMSz AT0000A18XM4 XSWX EQTC CH CHF CHF ESMA_E Deletion ARYZTA AG ARYNz CH0043238366 XSWX EQTB CH CHF CHF ESMA_E Deletion JULIUS BAER GRUPPE AG BAERz CH0102484968 XSWX EQTC CH CHF CHF ESMA_E Deletion BALOISE-HLDGS BALNz CH0012410517 XSWX EQTC CH CHF CHF ESMA_D Deletion BARRY CALLEBAUT AG BARNz CH0009002962 XSWX EQTC CH CHF CHF ESMA_D Deletion BB BIOTECH BBZAd CH0038389992 XETR EQTB DE EUR EUR ESMA_D Deletion BB BIOTECH BIONz CH0038389992 XSWX EQTB CH CHF CHF ESMA_D Deletion BASILEA PHARMACEUTICA AG BSLNz CH0011432447 XSWX EQTC CH CHF CHF ESMA_D Deletion BUCHER INDUSTRIES BUCNz CH0002432174 XSWX EQTC CH CHF CHF ESMA_D Deletion COMPAGNIE FINANCIERE RICHEMONT CFRz CH0210483332 XSWX EQTC CH CHF CHF ESMA_E Deletion CLARIANT CLNz CH0012142631 XSWX EQTC CH CHF CHF ESMA_E Deletion CEMBRA MONEY BANK AG CMBNz CH0225173167 XSWX EQTC CH CHF CHF ESMA_D Deletion CREDIT SUISSE GROUP AG CSGNz CH0012138530 XSWX EQTC CH CHF CHF ESMA_E Deletion DKSH HOLDING DKSHz CH0126673539 XSWX EQTC CH CHF CHF ESMA_D Deletion DORMA+KABA HOLDING AG DOKAz CH0011795959 XSWX EQTC CH CHF
    [Show full text]
  • 312.1.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1.
    [Show full text]
  • Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1
    Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1 [....] Annex A in relation to subsection 1.6 of the contract specifications: Futures on Shares of Produkt- Group Cash Contract Minimum Currency ID ID** Market- Size Price ID** Change* Julius Bär Holding AG - N. BAEG CH01 XSWX 50 0.0010.01 CHF BB Biotech AG BIOF CH01 XSWX 50 0.0010.01 CHF Logitech International S.A. - N. LOGF CH01 XSWX 100 0.00010.01 CHF Pargesa Holding S.A. PARF CH01 XSWX 10 0.0010.01 CHF Sonova Holding AG - N. PHBF CH01 XSWX 50 0.0010.01 CHF PSP Swiss Property AG - N. PSPF CH01 XSWX 50 0.0010.01 CHF Schindler Holding AG SINF CH01 XSWX 50 0.0010.01 CHF Straumann Holding AG STMF CH01 XSWX 10 0.0010.01 CHF Swatch Group AG, The - N. UHRF CH01 XSWX 100 0.00010.01 CHF Valiant Holding AG - N. VATF CH01 XSWX 10 0.0010.01 CHF ABB Ltd. ABBF CH02 XVTX 100 0.00010.01 CHF Adecco S.A. - N. ADEF CH02 XVTX 100 0.0010.01 CHF Actelion Ltd. - N. ATLG CH02 XVTX 50 0.0010.01 CHF Bâloise Holding AG BALF CH02 XVTX 100 0.0010.01 CHF Compagnie Financière Richemont AG CFRH CH02 XVTX 100 0.0010.01 CHF Ciba Spezialitätenchemie Holding AG - N. CIBF CH02 XVTX 10 0.0010.01 CHF Clariant AG - N. CLNF CH02 XVTX 100 0.00010.01 CHF Credit Suisse Group - N. CSGG CH02 XVTX 100 0.00010.01 CHF Geberit AG - N.
    [Show full text]
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • Corporate Governance
    Business report Corporate governance Transparency is one of the key elements of good corporate governance, to which Sonova is committed. Good corporate governance is essential for Sonova and we strive for high standards in this field. What “good corporate governance” means is an evolving matter and we constantly monitor the latest changes to the requirements. Compliance is an integral element of our corporate culture and embedded in our core values. We therefore continued to strengthen the Sonova Group compliance program during the 2017/18 financial year, putting particular emphasis on integrating our acquired businesses into our compliance culture, designing new global compliance training, and updating our antibribery policy. Our continuing compliance efforts help us to live our values of ethical behavior and unquestionable integrity. At Sonova, corporate governance is based upon, and structured to conform with, relevant standards and practices. The company fulfils its legal duties under the Swiss Code of Obligations, the SIX Swiss Exchange Directive on Information relating to Corporate Governance, and the standards defined in the Swiss Code of Best Practice for Corporate Governance. This report describes the principles of corporate governance for the Sonova Group and provides background information on the Group’s executive officers and bodies as of March 31, 2018. All relevant documents can be accessed at the corporate governance section of the Sonova website: www.sonova.com/en/commitments/corporategovernance. For clarity and transparency, the compensation report is presented as a separate chapter of the annual report. Sonova Annual Report 2017/18 37 CORPORATE GOVERNANCE Group structure Operational group structure The Sonova Group is headquartered in Stäfa, Switzerland, and is active in over 100 countries.
    [Show full text]
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]